Loading...
•
Jun 30, 2024
Apogee Q2 2024 Earnings Report
Apogee Therapeutics reported pipeline progress and second quarter 2024 financial results.
Key Takeaways
Apogee Therapeutics reported pipeline highlights and second quarter financial results, with a focus on advancing its pipeline, including APG777, APG808, and APG990, and adding APG333 to its portfolio. The company plans combination studies and has a cash runway into 2028.
Continued advancement of pipeline and execution towards expected milestones.
APG333, a novel subcutaneous half-life extended anti-TSLP antibody, was added to portfolio.
Apogee plans combination studies of 777 + 990 (IL-13 and OX40L) and 777 + 333 (IL-13 and TSLP).
$790 million cash, cash equivalents and marketable securities with runway into 2028.